The Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Citations Over TimeTop 12% of 1998 papers
Abstract
Although numerous studies have examined trends in nosocomial fungal infections, few have specifically addressed the cost of care associated with candidemia. This study analyzes the direct medical costs associated with treating candidemia in the United States. The study design was a cost-of-illness analysis estimating the average cost of candidemia for a single episode of care. Data were obtained from three sources: the 1993 Healthcare Cost and Utilization Project of the Agency for Health Care Policy and Research, the relevant literature, and a clinical expert in systemic fungal infections. The estimated cost (1997 U.S.$) of an episode of care for candidemia is $34,123 per Medicare patient and $44,536 per private insurance patient. The major cost associated with candidemia is that of an increased hospital stay. The estimated cost of care for candidemia may change in the future because of the use of more expensive antifungal treatments with improved safety and efficacy profiles.
Related Papers
- Advances in research on antifungal effect of natural plant components(2011)
- Study on Antifungal Activity of Self-made Combined Antifungal Agent to Color-deterioration Transfer Coating Leather(2007)
- Study on the Development of Combined Antifungal Agents Used in the Leather Industry(I):Comparison of Antifungal Effect of Single Compound(2005)
- → ChemInform Abstract: 3‐Imidazolyl‐Substituted Flavans as Potential Antifungal Agents: Synthesis, Stereochemical Properties and Antifungal Activity.(2009)